LitAlert ~~ GeneLit.com

    • Development of the PARP inhibitor talazoparib for the treatment of advanced BRCA1 and BRCA2 mutated breast cancer.
    • Hobbs EA, Litton JK, Yap TA.
    • Expert Opin Pharmacother. 2021 Jul 26:1-13. doi: 10.1080/14656566.2021.1952181. Epub ahead of print.
    • Review
    • Rapid progression of metastatic pancreatic adenocarcinoma during platinum-based therapy in a patient harboring a pathogenic BRCA2 germline variant.
    • Sorscher S, Ramkissoon S.
    • Oncologist. 2021 Jul 26. doi: 10.1002/onco.13912. Epub ahead of print.
    • A Real-World Evidence Study of CDK4/6 Inhibitor Treatment Patterns and Outcomes in Metastatic Breast Cancer by Germline BRCA Mutation Status.
    • Collins JM, Nordstrom BL, McLaurin KK, Dalvi TB, McCutcheon SC, Bennett JC, Murphy BR, Singhal PK, McCrea C, Shinde R, Briceno JM.
    • Oncol Ther. 2021 Jul 25. doi: 10.1007/s40487-021-00162-4. Epub ahead of print.
    • Optimizing the number of cycles of neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma: A propensity-score matching analysis.
    • Marchetti C, Rosati A, De Felice F, Boccia SM, Vertechy L, Pavone M, Palluzzi E, Scambia G, Fagotti A.
    • Gynecol Oncol. 2021 Jul 23:S0090-8258(21)00587-4. doi: 10.1016/j.ygyno.2021.07.025. Epub ahead of print.
    • What happens after menopause? (WHAM): A prospective controlled study of vasomotor symptoms and menopause-related quality of life 12 months after premenopausal risk-reducing salpingo-oophorectomy.
    • Hickey M, Moss KM, Krejany EO, Wrede CD, Brand A, Kirk J, Symecko HL, Domchek SM, Tejada-Berges T, Trainer A, Mishra GD.
    • Gynecol Oncol. 2021 Jul 23:S0090-8258(21)00591-6. doi: 10.1016/j.ygyno.2021.07.029. Epub ahead of print.
    • The preventive effect of breastfeeding against ovarian cancer in BRCA1 and BRCA2 mutation carriers: A systematic review and meta-analysis.
    • Eoh KJ, Park EY, Chang YJ, Ha HI, Hong J, Huang D, Nam EJ, Lim MC.
    • Gynecol Oncol. 2021 Jul 22:S0090-8258(21)00590-4. doi: 10.1016/j.ygyno.2021.07.028. Epub ahead of print.
    • Differential Activity of PARP Inhibitors in BRCA1- Versus BRCA2-Altered Metastatic Castration-Resistant Prostate Cancer.
    • Taza F, Holler AE, Fu W, Wang H, Adra N, Albany C, Ashkar R, Cheng HH, Sokolova AO, Agarwal N, Kessel A, Bryce A, Nafissi, N Barata, P Sartor AO, Bastos D, Smaletz O, Berchuck JE, Taplin ME, Aggarwal R, Sternberg CN, Vlachostergios PJ, Alva AS, Su C, Marshall CH, Antonarakis ES.
    • JCO Precis Oncol. 2021;5:1200. doi: 10.1200/PO.21.00070. Epub 2021 Jul 22.
    • Polygenic Breast Cancer Risk for Women Veterans in the Million Veteran Program.
    • Minnier J, Rajeevan N, Gao L, Park B, Pyarajan S,Spellman P; VA Million Veteran Program; Haskell SG, Brandt CA, Luoh SW.
    • JCO Precis Oncol. 2021;5:1178. doi: 10.1200/PO.20.00541. Epub 2021 Jul 21.
    • No Association of Early-Onset Breast or Ovarian Cancer with Early-Onset Cancer in Relatives in BRCA1 or BRCA2 Mutation Families.
    • Imbert-Bouteille M, Corsini C, Picot MC, Mizrahy L, Akouete S, Huguet H, Thomas F, Geneviève D, Taourel P, Ychou M, Galibert V, Rideau C, Baudry K, Kubiak TK, Coupier I, Hobeika R, Macary Y, Toledano A, Solassol J, Antoine Maalouf A, Daures JP, Pujol P.
    • Genes (Basel). 2021 Jul 20;12(7):1100. doi: 10.3390/genes12071100.
    • Classification of High-Grade Serous Ovarian Carcinoma by Epithelial-to-Mesenchymal Transition Signature and Homologous Recombination Repair Genes.
    • Sohn MH, Kim SI, Shin JY, Kim HS, Chung HH, Kim JW, Lee M, Seo JS.
    • Genes (Basel). 2021 Jul 20;12(7):1103. doi: 10.3390/genes12071103.
    • Efficacy and safety of PARP inhibitor combination therapy in recurrent ovarian cancer: a systematic review and meta-analysis.
    • Ren N, Zhang L, Yu J, Guan S, Dai X, Sun L, Ying M.
    • Front Oncol. 2021 Jul 19;10:638295. doi: 10.3389/fonc.2021.638295.
  • LitAlert ~~ GeneLit.com

    • Follow-up of tissue genomics in BRCA1/2 carriers who underwent prophylactic surgeries.
    • Kotoula V, Papadopoulou K, Tikas I, Fostira F, Vrettou E, Chrisafi S, Fountzilas E, Koliou GA, Apostolou P, Papazisis K, Zaramboukas T, Asimaki-Vlachopoulou A, Miliaras S, Ananiadis A, Poulios C, Natsiopoulos I, Tsiftsoglou A, Demiri E, Fountzilas G.
    • Breast Cancer. 2021 Jul 24. doi: 10.1007/s12282-021-01276-3. Epub ahead of print.
    • Association of somatic mutations in BRCA2 BRC domain with chemotherapy sensitivity and survival in high grade serous ovarian cancer.
    • Zhang G, Zhang J, Zhu Y, Liu H, Shi Y, Mi K, Li M, Zhao Q, Huang Z, Huang J.
    • Exp Cell Res. 2021 Jul 21:112742. doi: 10.1016/j.yexcr.2021.112742. Epub ahead of print.
    • Expanding the phenotype of E318K (c.952G > A) MITF germline mutation carriers: case series and review of the literature.
    • Oliveira LJC, Gongora ABL, Lima FAS, Canedo FSNA, Quirino CV, Pisani JP, Achatz MI, Rossi BM.
    • Hered Cancer Clin Pract. 2021 Jul 21;19(1):32. doi: 10.1186/s13053-021-00189-8.
    • Clinical biomarkers predicting the therapeutic effect of olaparib on platinum-sensitive recurrent ovarian cancer patients with unknown germline BRCA mutations.
    • Nakanishi K, Yamada T, Ishikawa G, Suzuki S.
    • Front Oncol. 2021 Jul 19;10:697952. doi: 10.3389/fonc.2021.697952.
    • Systemic therapy in metastatic pancreatic adenocarcinoma: current practice and perspectives.
    • Lellouche L, Palmieri LJ, Dermine S, Brezault C, Chaussade S, Coriat R.
    • Ther Adv Med Oncol. 2021 Jul 6;13:17588359211018539. doi: 10.1177/17588359211018539.
  • LitAlert ~~ GeneLit.com

    • Lynch syndrome-associated epithelial ovarian cancer and its immunological profile.
    • Rasmussen M, Lim K, Rambech E, Andersen MH, Svane IM, Andersen O, Jensen LH, Nilbert M, Therkildsen C.
    • Gynecol Oncol. 2021 Jul 15:S0090-8258(21)00531-X. doi: 10.1016/j.ygyno.2021.07.001. Epub ahead of print.
    • Involvement of ATMIN-DYNLL1-MRN axis in the progression and aggressiveness of serous ovarian cancer.
    • Berkel C, Cacan E.
    • Biochem Biophys Res Commun. 2021 Jul 14;570:74-81. doi: 10.1016/j.bbrc.2021.07.004. Epub ahead of print.
    • 25-year perspective on prostate cancer: Conquering frontiers and understanding tumor biology.
    • Dorff TB, O'Neil B, Hoffman KE, Lin DW, Loughlin KR, Dall'Era M.
    • Urol Oncol. 2021 Jul 12:S1078-1439(21)00175-7. doi: 10.1016/j.urolonc.2021.04.016. Epub ahead of print.
    • Review
    • Expanding the search for germline pathogenic variants for breast cancer. How far should we go and how high should we jump? The missed opportunity!
    • Abdel-Razeq H.
    • Oncol Rev. 2021 Jun 24;15(1):544. doi: 10.4081/oncol.2021.544.
    • COVID-19 Vaccination Induced Lymphadenopathy in a Specialized Breast Imaging Clinic in Israel: Analysis of 163 cases.
    • Faermann R, Nissan N, Halshtok-Neiman O, Shalmon A, Gotlieb M, Yagil Y, Samoocha D, Friedman E, Sklair-Levy M.
    • Acad Radiol. 2021 Jun 10:S1076-6332(21)00273-7. doi: 10.1016/j.acra.2021.06.003. Epub ahead of print.
    • Prevalence of Germline Alterations on Targeted Tumor-Normal Sequencing of Esophagogastric Cancer.
    • Ku GY, Kemel Y, Maron SB, Chou JF, Ravichandran V, Shameer Z, Maio A, Won ES, Kelsen DP, Ilson DH, Capanu M, Strong VE, Molena D, Sihag S, Jones DR, Coit DG, Tuvy Y, Cowie K, Solit DB, Schultz N, Hechtman JF, Offit K, Joseph V, Mandelker D, Janjigian YY, Stadler ZK.
    • JAMA Netw Open. 2021 Jul 1;4(7):e2114753. doi: 10.1001/jamanetworkopen.2021.14753.

    Commentary:

    Expanding Germline Testing to All Patients With Esophagogastric Cancers-Easy to Do, Harder to Justify.

    Press: Gastric Cancer Cases Frequently Harbor Genetic Risk Variants, Suggesting Germline Testing. (GenomeWeb)

  • LitAlert ~~ GeneLit.com

    • Anti-müllerian hormone levels and antral follicle count in women with a BRCA1 or BRCA2 germline pathogenic variant: A retrospective cohort study.
    • Denis-Laroque L, Drouet Y, Plotton I, Chopin N, Bonadona V, Lornage J, Salle B, Lasset C, Jablonski CR.
    • Breast. 2021 Jul 12:S0960-9776(21)00416-1. doi: 10.1016/j.breast.2021.07.010. Epub ahead of print.
    • The germline/somatic DNA damage repair gene mutations modulate the therapeutic response in Chinese patients with advanced pancreatic ductal adenocarcinoma.
    • Shui L, Li X, Peng Y, Tian J, Li S, He D, Li A, Tian B, Li M, Gao H, An N, Yi C, Cao D.
    • J Transl Med. 2021 Jul 12;19(1):301. doi: 10.1186/s12967-021-02972-6.
    • Genetic analysis of functional rare germline variants across 9 cancer types from an electronic health record linked biobank.
    • Shivakumar M, Miller JE, Dasari VR, Zhang Y, Lee MTM, Carey DJ, Gogoi R, Kim D.
    • Cancer Epidemiol Biomarkers Prev. 2021 Jul 8:cebp.EPI-21-0082-E.2021. doi: 10.1158/1055-9965.EPI-21-0082. Epub ahead of print.
    • BRCA, breast cancer and in vitro fertilization: How should we advise our patients?
    • García-Planells J, Francés BS, Diez-Juan A.
    • Fertil Steril. 2021 Jul 8:S0015-0282(21)00505-7. doi: 10.1016/j.fertnstert.2021.06.011. Epub ahead of print.

    Original research:

    Fertility treatments and breast cancer risk in Jewish Israeli BRCA mutation carriers.

    • Olaparib as maintenance therapy and salvage therapy in recurrent ovarian cancer: The early experience in Taiwan.
    • Hsu CC, Pan YB, Lai CH, Chang TC, Yang LY, Chou HH.
    • Taiwan J Obstet Gynecol. 2021 Jul;60(4):634-638. doi: 10.1016/j.tjog.2021.05.010.
  • LitAlert ~~ GeneLit.com

    • The correlation between BRCA status and surgical cytoreduction in high-grade serous ovarian carcinoma.
    • Kim SR, Malcolmson J, Li X, Bernardini MQ, Hogen L, May T.
    • Gynecol Oncol. 2021 Jul 10:S0090-8258(21)00540-0. doi: 10.1016/j.ygyno.2021.07.010. Epub ahead of print.
    • Case-case analysis addressing ascertainment bias for multigene panel testing implicates BRCA1 and PALB2 in endometrial cancer.
    • Johnatty SE, Pesaran T, Dolinsky J, Yussuf A, La Duca H, James PA, Mara TAO, Spurdle AB.
    • Hum Mutat. 2021 Jul 10. doi: 10.1002/humu.24256. Epub ahead of print.
    • Dose-dependent effects of aerobic exercise on clinically relevant biomarkers among healthy women at high genetic risk for breast cancer: A secondary analysis of a randomized controlled study.
    • Ehret CJ, Zhou S, Tchou JC, Schmitz KH, Sturgeon KM.
    • Cancer Rep (Hoboken). 2021 Jul 9:e1497. doi: 10.1002/cnr2.1497. Epub ahead of print.
    • Cost-effectiveness analysis of olaparib and niraparib as maintenance therapy for women with recurrent platinum-sensitive ovarian cancer.
    • Leung JH, Lang HC, Wang SY, Lo HF, Chan AL.
    • Expert Rev Pharmacoecon Outcomes Res. 2021 Jul 9. doi: 10.1080/14737167.2021.1954506. Epub ahead of print.
    • Assistance by routine CT features combined with 3D texture analy- sis in the diagnosis of BRCA gene mutation status in advanced epithelial ovarian cancer.
    • LI MR, wei W, Liu MZ, Zhou Y, Ya-qiong GE.
    • Front Oncol. 2021 Jul 8;10:716467. doi: 10.3389/fonc.2021.696780.
    • Differences in Ovarian and Other Cancers Risks by Population and BRCA Mutation Location.
    • Sekine M, Nishino K, Enomoto T.
    • Genes (Basel). 2021 Jul 8;12(7):1050. doi: 10.3390/genes12071050.
    • Indirect treatment comparison of olaparib and talazoparib in germline BRCA-mutated HER2-negative metastatic breast cancer.
    • McCrea C, Hettle R, Gulati P, Taneja A, Rajora P.
    • J Comp Eff Res. 2021 Jul 7. doi: 10.2217/cer-2021-0097. Epub ahead of print.
    • Review
    • A competing risks model with binary time varying covariates for estimation of breast cancer risks in BRCA1 families.
    • Briollais L.
    • Stat Methods Med Res. 2021 Jul 7:9622802211008945. doi: 10.1177/09622802211008945. Epub ahead of print.
    • Ten years follow-up of histologically benign calcifications in the breast after vacuum-assisted stereotactic biopsy (VASB): Is additional mammographic follow-up warranted?
    • van Bekkum S, Dams FEM, Westenend PJ, van Rosmalen J, Menke-Pluijmers MBE, Kock MCJM.
    • Breast. 2021 Jun 26;59:135-143. doi: 10.1016/j.breast.2021.06.008. Epub ahead of print.
  • LitAlert ~~ GeneLit.com

    • Influence of aging and gadolinium exposure on T1, T2, and T2*-relaxation in healthy women with an increased risk of breast cancer with and without prior exposure to gadoterate meglumine at 3.0-T brain MR imaging.
    • Krug KB, Burke CJ, Weiss K, Baltzer PAT, Rhiem K, Maintz D, Schlamann M, Hellmich M.
    • Eur Radiol. 2021 Jul 3. doi: 10.1007/s00330-021-08069-4. Epub ahead of print.
    • Study: Cancer risks of people with inherited PALB2 mutations.
    • [No author given]
    • FORCE. XRAY. 2021 Jul 1.

    Original research:

    Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families.

  • LitAlert ~~ GeneLit.com

    • Blood Arsenic Levels as a Marker of Breast Cancer Risk among BRCA1 Carriers.
    • Marciniak W, Matoušek T, Domchek S, Paradiso A, Patruno M, Irmejs A, Roderte I, Derkacz R, Baszuk P, Kuswik M, Cybulski C, Huzarski T, Gronwald J, Debniak T, Falco M, Lener MR, Jakubowska A, Katherine Pullella K, Kotsopoulos J, Narod S, Lubinski J.
    • Cancers (Basel). 2021 Jul 3;13(13):3345. doi: 10.3390/cancers13133345.
    • Risk of cardiovascular disease among women carrying BRCA mutations after risk-reducing bilateral salpingo-oophorectomy: A population-based study.
    • Abreu do Valle H, Kaur P, Kwon JS, Cheifetz R, Dawson L, Hanley GE.
    • Gynecol Oncol. 2021 Jul 1:S0090-8258(21)00520-5. doi: 10.1016/j.ygyno.2021.06.022. Epub ahead of print.
  • LitAlert ~~ GeneLit.com

    • Circulating tumor DNA reveals genetic traits of patients with intraductal carcinoma of the prostate.
    • Zhao J, Sun G, Zhu S, Dai J, Chen J, Zhang M, Ni Y, Zhang H, Shen P, Zhao X, Zhang B, Pan X, Nie L, Yin X, Liang J, Zhang X, Wang Z, Zhu X, Liao B, Liu Z, Armstrong CM, Gao AC, Huang H, Chen N, Zeng H.
    • BJU Int. 2021 Jun 29. doi: 10.1111/bju.15530. Epub ahead of print.
    • Impact of breast cancer risk factors on clinically relevant prognostic biomarkers for primary breast cancer.
    • Abubakar M, Guo C, Koka H, Zhu B, Deng J, Hu N, Zhou B, Garcia-Closas M, Lu N, Yang XR.
    • Breast Cancer Res Treat. 2021 Jun 29. doi: 10.1007/s10549-021-06294-5. Epub ahead of print.